Gut bacteria markers could be a ‘smoking gun’ for liver disease
New enzyme boost could hasten biofuel production
Greener energy generation alone will not help us reach climate goals
Focused on understanding brain development and injury in newborns, and evaluating novel therapies to protect the newborn brain
We are deploying quantitative MR biomarkers to understand brain injury in full-term babies and to evaluate the treatment effect of neuroprotective therapies.
Find out more
We are using quantitative MR biomarkers to understand preterm brain injury, especially the association of in-utero microbiomes and systemic illness on preterm brain injury and development.
Our work is focused on improving the neurological outcomes of babies born in low- and middle-income countries.